Jim Tananbaum

Foresite Capital Managing Partner

Photo of Jim Tananbaum, Managing Partner at Foresite Capital
CompanyDeal TypeAmountDate
InsitroSeries AMay 2018
JuvenescenceSeed Round$12.3M (Lead)Jan 2018
DNAnexusSeries E$58M (Lead)Jan 2018
LifeMine TherapeuticsSeries A$55MSep 2017
Aimmune TherapeuticsSeries B$80M (Lead)Mar 2015
Tarsa TherapeuticsSeries B$7MMay 2014
Intarcia TherapeuticsSeries D$200MApr 2014
SequentaSeries C$20M (Lead)Jul 2013
Tarsa TherapeuticsSeries B$28M (Lead)Mar 2012
Founder and CEO Foresite Capital Management2010 - Present
Co-Founder and Managing Director PVP2 & PVP3 Prospect Venture Partners2001 - 2010
Co-Founder and Chief Executive Officer Theravance (THRX)1997 - 2000
Partner Sierra Ventures1993 - 1997
Co-Founder and CEO GelTex (acquired by Genzyme for $1.6 B)1991 - 1992
Harvard Business School mba
Harvard Medical School Doctor of Medicine (MD)
Massachusetts Institute of Technology Master of Science (M.S.) HST - information theory
Yale University BS BSEE, Math, computer science
No media found for Jim Tananbaum.
cb
Photo of Brett Zbar, Managing Partner at Foresite Capital

Foresite Capital

Photo of Christine Aylward, Managing Partner at Foresite Capital

Foresite Capital

Photo of Dennis Ryan, Managing Partner at Foresite Capital

Foresite Capital

Photo of Dorothy Margolskee, Managing Partner at Foresite Capital

Foresite Capital

Photo of Linda Shaffer, Foresite Capital

Foresite Capital